Influenza Virus and Rhinovirus-related Otitis Media: Potential for Antiviral Intervention

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2001 Feb 13

PMID 11163466

Citations 9

Authors

F G Hayden

Affiliations

Soon will be listed here.

Abstract

Adults frequently develop eustachian tube dysfunction and middle ear pressure (MEP) abnormalities during natural and experimental influenza and human rhinovirus (HRV) infections. Oral rimantadine treatment did not reduce the otologic manifestations of experimental influenza in adults or natural influenza in children. However, intranasal zanamivir and oral oseltamivir significantly reduced MEP abnormalities during experimental influenza in adults, and oseltamivir treatment appears to reduce the likelihood of otitis media in children with acute influenza. Investigational anti-HRV agents, including intranasal tremacamra, intranasal AG7088, and oral pleconaril, warrant study in this regard. Depending on the virus, early antiviral therapy has the potential to impact the risk of otitis media following respiratory tract infections.

Citing Articles

Occurrence of acute otitis and sinusitis in patients hospitalized for influenza.

Plesca V, Marinescu A, Voiosu C, Draganescu A, Streinu-Cercel A, Vilaia A Germs. 2024; 14(1):38-44.

PMID: 39169978 PMC: 11333841. DOI: 10.18683/germs.2024.1416.

Toxic inner ear lesion following otitis media with effusion: a comparative CT-study regarding the morphology of the inner ear.

Wilhelm T, Stelzer T, Wiegand S, Guldner C, Teymoortash A, Gunzel T Eur Arch Otorhinolaryngol. 2014; 272(12):3635-43.

PMID: 25481029 DOI: 10.1007/s00405-014-3425-4.

Immunopathogenesis of polymicrobial otitis media.

Bakaletz L J Leukoc Biol. 2009; 87(2):213-22.

PMID: 19843575 PMC: 2812561. DOI: 10.1189/jlb.0709518.

The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery.

Rollinger J, Schmidtke M Med Res Rev. 2009; 31(1):42-92.

PMID: 19714577 PMC: 7168442. DOI: 10.1002/med.20176.

Inhibition of rhinovirus replication in vitro and in vivo by acid-buffered saline.

Gern J, Mosser A, Swenson C, Rennie P, England R, Shaffer J J Infect Dis. 2007; 195(8):1137-43.

PMID: 17357049 PMC: 7110134. DOI: 10.1086/512858.

References

Henderson F, Collier A, Sanyal M, Watkins J, Fairclough D, CLYDE Jr W . A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion. N Engl J Med. 1982; 306(23):1377-83. DOI: 10.1056/NEJM198206103062301. View

Hayden F, Hipskind G, Woerner D, Eisen G, Janssens M, Janssen P . Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother. 1995; 39(2):290-4. PMC: 162529. DOI: 10.1128/AAC.39.2.290. View

Heikkinen T, Thint M, Chonmaitree T . Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med. 1999; 340(4):260-4. DOI: 10.1056/NEJM199901283400402. View

Arruda E, Pitkaranta A, Witek Jr T, Doyle C, Hayden F . Frequency and natural history of rhinovirus infections in adults during autumn. J Clin Microbiol. 1997; 35(11):2864-8. PMC: 230076. DOI: 10.1128/jcm.35.11.2864-2868.1997. View

Pitkaranta A, Virolainen A, Jero J, Arruda E, Hayden F . Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics. 1998; 102(2 Pt 1):291-5. DOI: 10.1542/peds.102.2.291. View

Pitkaranta A, Jero J, Arruda E, Virolainen A, Hayden F . Polymerase chain reaction-based detection of rhinovirus, respiratory syncytial virus, and coronavirus in otitis media with effusion. J Pediatr. 1998; 133(3):390-4. PMC: 7095025. DOI: 10.1016/s0022-3476(98)70276-8. View

Sung B, Chonmaitree T, Broemeling L, Owen M, Patel J, Hedgpeth D . Association of rhinovirus infection with poor bacteriologic outcome of bacterial-viral otitis media. Clin Infect Dis. 1993; 17(1):38-42. DOI: 10.1093/clinids/17.1.38. View

Hall C, Dolin R, Gala C, Markovitz D, Zhang Y, Madore P . Children with influenza A infection: treatment with rimantadine. Pediatrics. 1987; 80(2):275-82. View

Doyle W, Skoner D, Alper C, Allen G, Moody S, Seroky J . Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. J Infect Dis. 1998; 177(5):1260-5. DOI: 10.1086/515294. View

10.

Walker J, Hussey E, Treanor J, Montalvo Jr A, Hayden F . Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza. J Infect Dis. 1997; 176(6):1417-22. DOI: 10.1086/514136. View

11.

Elkhatieb A, Hipskind G, Woerner D, Hayden F . Middle ear abnormalities during natural rhinovirus colds in adults. J Infect Dis. 1993; 168(3):618-21. DOI: 10.1093/infdis/168.3.618. View

12.

Sperber S, Doyle W, McBride T, Sorrentino J, Riker D, Hayden F . Otologic effects of interferon beta serine in experimental rhinovirus colds. Arch Otolaryngol Head Neck Surg. 1992; 118(9):933-6. DOI: 10.1001/archotol.1992.01880090049015. View

13.

Moody S, Alper C, Doyle W . Daily tympanometry in children during the cold season: association of otitis media with upper respiratory tract infections. Int J Pediatr Otorhinolaryngol. 1998; 45(2):143-50. DOI: 10.1016/s0165-5876(98)00103-7. View

14.

Turner R, Wecker M, Pohl G, Witek T, McNally E, George R . Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA. 1999; 281(19):1797-804. DOI: 10.1001/jama.281.19.1797. View

15.

Schiff G, Sherwood J . Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis. 1999; 181(1):20-6. DOI: 10.1086/315176. View

16.

Hayden F, Treanor J, Fritz R, Lobo M, Betts R, Miller M . Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999; 282(13):1240-6. DOI: 10.1001/jama.282.13.1240. View

17.

Hayden F, Andries K, Janssen P . Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother. 1992; 36(4):727-32. PMC: 189373. DOI: 10.1128/AAC.36.4.727. View